Initiation of antiretroviral therapy at high CD4 cell counts: Does it reduce the risk of cardiovascular disease?

Current Opinion in HIV and AIDS

Volumn 9, Issue 1, 2014, Pages 54-62

  Longenecker, Chris T ^a   Triant, Virginia A ^b  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

antiretroviral therapy; cardiovascular disease; heart failure; immune activation; sudden cardiac death

Indexed keywords

ANTIRETROVIRUS AGENT;

ANTIVIRAL THERAPY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CD4 LYMPHOCYTE COUNT; DISEASE ASSOCIATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DYSREGULATION; IMMUNE STATUS; INFLAMMATION; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; VIRUS REPLICATION;

ANTI-RETROVIRAL AGENTS; CARDIOVASCULAR DISEASES; CD4 LYMPHOCYTE COUNT; HIV INFECTIONS; HUMANS;

EID: 84892372114     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0000000000000015     Document Type: Review

References (109)

1. Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab 2007; 92: 2506-2512
2. Freiberg MS, Chang CC, Kuller LH, et al. HIV infection and the risk of acute myocardial infarction. JAMA Intern Med 2013; 173: 614-622
3. Freiberg MS, Chang CC, Skanderson M, et al. The risk of incident coronary heart disease among veterans with and without HIV and hepatitis C. Circ Cardiovasc Qual Outcomes 2011; 4: 425-432
4. Chow FC, Regan S, Feske S, et al. Comparison of ischemic stroke incidence in HIV-infected and non-HIV-infected patients in a US healthcare system. J Acquir Immune Defic Syndr 2012; 60: 351-358
5. Butt AA, Chang CC, Kuller L, et al. Risk of heart failure with human immunodeficiency virus in the absence of prior diagnosis of coronary heart disease. Arch Intern Med 2011; 171: 737-743
6. Freiberg M, Chang CC, Oursler KA, et al. The risk of and survival with preserved vs. reduced ejection fraction heart failure by HIV status. 20th conference on retroviruses and opportunistic infections; Atlanta, GA, USA; 2013
7. Hsu JC, Li Y, Marcus GM, et al. Atrial fibrillation and atrial flutter in HIVinfected persons: Incidence, risk factors, and association with markers of HIV disease severity. J Am Coll Cardiol 2013; 61: 2288-2295
8. Tseng ZH, Secemsky EA, Dowdy D, et al. Sudden cardiac death in patients with human immunodeficiency virus infection. J Am Coll Cardiol 2012; 59: 1891-1896
9. Smith C, Sabin CA, Lundgren JD, et al. Factors associated with specific causes of death amongst HIV-positive individuals in the D: A: D study. AIDS 2010; 24: 1537-1548
10. Sabin C, Ryom L, Law M, et al. Improvements in short-Term mortality following myocardial infarction: The data collection on adverse events of anti-HIV drugs study. 20th conference on retroviruses and opportunistic infections; Atlanta, GA, USA; 2013
11. Longenecker CT, Hoit BD. Imaging atherosclerosis in HIV: Carotid intimamedia thickness and beyond. Transl Res 2012; 159: 127-139
12. Zanni MV, Abbara S, Lo J, et al. Increased coronary atherosclerotic plaque vulnerability by coronary computed tomography angiography in HIV-infected men. AIDS 2013; 27
13. Hsue PY, Ordovas K, Lee T, et al. Carotid intima-media thickness among human immunodeficiency virus-infected patients without coronary calcium. Am J Cardiol 2012; 109: 742-747
14. Triant VA, Regan S, Lee H, et al. Association of immunologic and virologic factors with myocardial infarction rates in a US healthcare system. J Acquir Immune Defic Syndr 2010; 55: 615-619
15. Friis-Moller N, Reiss P, Sabin CA, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007; 356: 1723-1735
16. Hsue PY, Deeks SG, Hunt PW. Immunologic basis of cardiovascular disease in HIV-infected adults. J Infect Dis 2012; 205 (Suppl 3): S375-S382
17. El-Sadr WM, Lundgren J, Neaton JD, et al. CD4 count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355: 2283-2296
18. Phillips AN, Carr A, Neuhaus J, et al. Interruption of antiretroviral therapy and risk of cardiovascular disease in persons with HIV-1 infection: Exploratory analyses from the SMART trial. Antivir Ther 2008; 13: 177-187
19. Kitahata MM, Gange SJ, Abraham AG, et al. Effect of early versus deferred antiretroviral therapy for HIV on survival.NEngl J Med 2009; 360: 1815-1826
20. Babiker AG, Emery S, Fatkenheuer G, et al. Considerations in the rationale, design and methods of the Strategic Timing of AntiRetroviral Treatment (START) study. Clin Trials 2012; 10 (1 Suppl): S5-S36
21. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. http: //aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf. [Accessed 14 May 2013
22. Florence E, Lundgren J, Dreezen C, et al. Factors associated with a reduced CD4 lymphocyte count response to HAART despite full viral suppression in the EuroSIDA study. HIV Med 2003; 4: 255-262
23. van Lelyveld SF, Gras L, Kesselring A, et al. Long-Term complications in patients with poor immunological recovery despite virological successful HAART in Dutch ATHENA cohort. AIDS 2012; 26: 465-474
24. Helleberg M, Kronborg G, Larsen CS, et al. CD4 decline is associated with increased risk of cardiovascular disease, cancer, and death in virally suppressed patients with HIV. Clin Infect Dis 2013; 57: 314-321
25. Lang S, Mary-KrauseM, Simon A, et al. HIV replication and immune status are independent predictors of the risk of myocardial infarction in HIV-infected individuals. Clin Infect Dis 2012; 55: 600-607
26. Lichtenstein KA, Armon C, Buchacz K, et al. Low CD4 T cell count is a risk factor for cardiovascular disease events in the HIV outpatient study. Clin Infect Dis 2010; 51: 435-447
27. Lucero C, Torres B, Leon A, et al. Rate and predictors of non-AIDS events in a cohort of HIV-infected patients with a CD4 T cell count above 500 cells/mm. AIDS Res Hum Retroviruses 2013; 29: 1161-1167
28. Ford ES, Greenwald JH, Richterman AG, et al. Traditional risk factors and Ddimer predict incident cardiovascular disease events in chronic HIV infection. AIDS 2010; 24: 1509-1517
29. Sabin CA, Ryom L, De Wit S, et al. Associations between immune depression and cardiovascular events in HIV infection. AIDS 2013. [Epub ahead of print]
30. Kaplan RC, Kingsley LA, Gange SJ, et al. Low CD4 T-cell count as a major atherosclerosis risk factor in HIV-infected women and men. AIDS 2008; 22: 1615-1624
31. Hsue PY, Lo JC, Franklin A, et al. Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection. Circulation 2004; 109: 1603-1608
32. Seaberg EC, Benning L, Sharrett AR, et al. Association between human immunodeficiency virus infection and stiffness of the common carotid artery. Stroke 2010; 41: 2163-2170
33. Ho JE, Deeks SG, Hecht FM, et al. Initiation of antiretroviral therapy at higher nadir CD4 T-cell counts is associated with reduced arterial stiffness in HIVinfected individuals. AIDS 2010; 24: 1897-1905
34. Papasavvas E, Hsue P, Reynolds G, et al. Increased CD34/KDR cells are not associated with carotid artery intima-media thickness progression in chronic HIV-positive subjects. Antivir Ther 2012; 17: 557-563
35. Ho JE, Scherzer R, Hecht FM, et al. The association of CD4 T-cell counts and cardiovascular risk in treated HIV disease. AIDS 2012; 26: 1115-1120
36. Hsue PY, Hunt PW, Ho JE, et al. Impact of HIV infection on diastolic function and left ventricular mass. Circ Heart Fail 2010; 3: 132-139
37. Manner IW, Troseid M, Oektedalen O, et al. Low nadir CD4 cell count predicts sustained hypertension in HIV-infected individuals. J Clin Hypertens (Greenwich) 2013; 15: 101-106
38. Guaraldi G, Zona S, Alexopoulos N, et al. Coronary aging in HIV-infected patients. Clin Infect Dis 2009; 49: 1756-1762
39. Kingsley LA, Cuervo-Rojas J, Munoz A, et al. Subclinical coronary atherosclerosis, HIV infection and antiretroviral therapy: Multicenter AIDS Cohort Study. AIDS 2008; 22: 1589-1599
40. Guaraldi G, Zona S, Orlando G, et al. Progression of coronary artery calcium in men affected by human immunodeficiency virus infection. Int J Cardiovasc Imaging 2012; 28: 935-941
41. Guaraldi G, Scaglioni R, Zona S, et al. Epicardial adipose tissue is an independent marker of cardiovascular risk in HIV-infected patients. AIDS 2011; 25: 1199-1205
42. Longenecker CT, Jiang Y, Yun CH, et al. Perivascular fat, inflammation, and cardiovascular risk in HIV-infected patients on antiretroviral therapy. Int J Cardiol 2013. [Epub ahead of print
43. Burdo TH, Lo J, Abbara S, et al. Soluble CD163, a novel marker of activated macrophages, is elevated and associated with noncalcified coronary plaque in HIV-infected patients. J Infect Dis 2011; 204: 1227-1236
44. Mellors JW, Munoz A, Giorgi JV, et al. Plasma viral load and CD4 lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997; 126: 946-954
45. Reekie J, Gatell JM, Yust I, et al. Fatal and nonfatal AIDS and non-AIDS events in HIV-1-positive individuals with high CD4 cell counts according to viral load strata. AIDS 2011; 25: 2259-2268
46. Zhang S, van Sighem A, Kesselring A, et al. Episodes of HIV viremia and the risk of non-AIDS diseases in patients on suppressive antiretroviral therapy. J Acquir Immune Defic Syndr 2012; 60: 265-272
47. Baker JV, Henry WK, Patel P, et al. Progression of carotid intima-media thickness in a contemporary human immunodeficiency virus cohort. Clin Infect Dis 2011; 53: 826-835
48. Stein JH, Brown TT, Ribaudo HJ, et al. Ultrasonographic measures of cardiovascular disease risk in antiretroviral treatment-naive individuals with HIV infection. AIDS 2012; 27: 929-937
49. Torriani FJ, Komarow L, Parker RA, et al. Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: The ACTG (AIDS Clinical Trials Group) Study 5152s. J Am Coll Cardiol 2008; 52: 569-576
50. Arildsen H, Sorensen KE, Ingerslev JM, et al. Endothelial dysfunction, increased inflammation, and activated coagulation in HIV-infected patients improve after initiation of highly active antiretroviral therapy. HIV Med 2013; 14: 1-9
51. Pereyra F, Lo J, Triant VA, et al. Increased coronary atherosclerosis and immune activation in HIV-1 elite controllers. AIDS 2012; 26: 2409-2412
52. Hsue PY, Hunt PW, Schnell A, et al. Role of viral replication, antiretroviral therapy, and immunodeficiency in HIV-Associated atherosclerosis. AIDS 2009; 23: 1059-1067
53. Duprez DA, Neuhaus J, Kuller LH, et al. Inflammation, coagulation and cardiovascular disease in HIV-infected individuals. PLoS One 2012; 7: E44454
54. Triant VA, Meigs JB, Grinspoon SK. Association of C-reactive protein and HIV infection with acute myocardial infarction. J Acquir Immune Defic Syndr 2009; 51: 268-273
55. Hsue PY, Scherzer R, Hunt PW, et al. Carotid intima-media thickness progression in HIV-infected adults occurs preferentially at the carotid bifurcation and is predicted by inflammation. J Am Heart Assoc 2012; 1: Jah3-e000422
56. Mangili A, Polak JF, Skinner SC, et al. HIV infection and progression of carotid and coronary atherosclerosis: The CARE study. J Acquir Immune Defic Syndr 2011; 58: 148-153
57. Cerrato E, D'Ascenzo F, Biondi-Zoccai G, et al. Cardiac dysfunction in pauci symptomatic human immunodeficiency virus patients: A meta-Analysis in the highly active antiretroviral therapy era. Eur Heart J 2013; 34: 1432-1436
58. Longenecker C, Funderburg N, Jiang Y, et al. Markers of inflammation and CD8 T-cell activation, but not monocyte activation, are associated with subclinical carotid artery disease in HIV-infected individuals. HIV Med 2013; 14: 385-390
59. Kaplan RC, Landay AL, Hodis HN, et al. Potential cardiovascular disease risk markers among HIV-infected women initiating antiretroviral treatment. J Acquir Immune Defic Syndr 2012; 60: 359-368
60. Hileman CO, Longenecker CT, Carman TL, et al. Elevated D-dimer is independently associated with endothelial dysfunction: A cross-sectional study in HIV-infected adults on antiretroviral therapy. Antivir Ther 2012; 17: 1345-1349
61. Subramanian S, Tawakol A, Burdo TH, et al. Arterial inflammation in patients with HIV. JAMA 2012; 308: 379-386
62. Kaplan RC, Sinclair E, Landay AL, et al. T cell activation and senescence predict subclinical carotid artery disease in HIV-infected women. J Infect Dis 2011; 203: 452-463
63. Kaplan RC, Sinclair E, Landay AL, et al. T cell activation predicts carotid artery stiffness among HIV-infected women. Atherosclerosis 2011; 217: 207-213
64. Funderburg NT, Zidar DA, Shive C, et al. Shared monocyte subset phenotypes in HIV-1 infection and in uninfected subjects with acute coronary syndrome. Blood 2012; 120: 4599-4608
65. Sandler NG, Wand H, Roque A, et al. Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis 2011; 203: 780-790
66. Justice AC, Freiberg MS, Tracy R, et al. Does an index composed of clinical data reflect effects of inflammation, coagulation, and monocyte activation on mortality among those aging with HIV? Clin Infect Dis 2012; 54: 984-994
67. Blodget E, Shen C, Aldrovandi G, et al. Relationship between microbial translocation and endothelial function in HIV infected patients. PLoS One 2012; 7: E42624
68. Merlini E, Luzi K, Suardi E, et al. T-cell phenotypes, apoptosis and inflammation in HIV patients on virologically effective cART with early atherosclerosis. PLoS One 2012; 7: E46073
69. Kelesidis T, Kendall MA, Yang OO, et al. Biomarkers of microbial translocation and macrophage activation: Association with progression of subclinical atherosclerosis in HIV-1 infection. J Infect Dis 2012; 206: 1558-1567
70. Burdo TH, Lentz MR, Autissier P, et al. Soluble CD163 made by monocyte/ macrophages is a novel marker of HIV activity in early and chronic infection prior to and after antiretroviral therapy. J Infect Dis 2011; 204: 154-163
71. Zanni MV, Burdo TH, Makimura H, et al. Relationship between monocyte/ macrophage activation marker soluble CD163 and insulin resistance in obese and normal-weight subjects. Clin Endocrinol (Oxf) 2012; 77: 385-390
72. Gupta SK, Johnson RM, Saha C, et al. Improvement in HIV-related endothelial dysfunction using the anti-inflammatory agent salsalate: A pilot study. AIDS 2008; 22: 653-655
73. Hileman CO, Carman TL, Gripshover BM, et al. Salsalate is poorly tolerated and fails to improve endothelial function in virologically suppressed HIVinfected adults. AIDS 2010; 24: 1958-1961
74. Gupta SK, Mi D, Dube MP, et al. Pentoxifylline, inflammation, and endothelial function in HIV-infected persons: A randomized, placebo-controlled trial. PLoS One 2013; 8: E60852
75. Ganesan A, Crum-Cianflone N, Higgins J, et al. High dose atorvastatin decreases cellular markers of immune activation without affecting HIV-1 RNA levels: Results of a double-blind randomized placebo controlled clinical trial. J Infect Dis 2011; 203: 756-764
76. McComsey G, Jiang Y, Debanne S, et al. Effect of statins on immune activation and inflammation in HIV subjects on ART: A randomized placebo controlled trial. 20th conference on retroviruses and opportunistic infections; Atlanta, GA USA; 2013. Abstract #186LB
77. O'Brien M, Montenont E, Hu L, et al. Aspirin attenuates platelet activation and immune activation in HIV-infected subjects on antiretroviral therapy: A pilot study. J Acquir Immune Defic Syndr 2013; 63: 280-288
78. Moore RD, Bartlett JG, Gallant JE. Association between use of HMG CoA reductase inhibitors and mortality in HIV-infected patients. PLoS One 2011; 6: E21843
79. Rasmussen LD, Kronborg G, Larsen CS, et al. Statin therapy and mortality in HIV-infected individuals; a Danish nationwide population-based cohort study. PLoS One 2013; 8: E52828
80. Bavinger C, Bendavid E, Niehaus K, et al. Risk of cardiovascular disease from antiretroviral therapy for HIV: A systematic review. PLoS One 2013; 8: E59551
81. Islam FM, Wu J, Jansson J, Wilson DP. Relative risk of cardiovascular disease among people living with HIV: A systematic review and meta-Analysis. HIV Med 2012; 13: 453-468
82. Monforte A, Reiss P, Ryom L, et al. Atazanavir is not associated with an increased risk of cardio or cerebrovascular disease events. AIDS 2013; 27: 407-415
83. Sabin CA, Worm SW, Weber R, et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D: A: D study: A multicohort collaboration. Lancet 2008; 371: 1417-1426
84. Hsue PY, Hunt PW, Wu Y, et al. Association of abacavir and impaired endothelial function in treated and suppressed HIV-infected patients. AIDS 2009; 23: 2021-2027
85. McComsey GA, Kitch D, Daar ES, et al. Inflammation markers after randomization to abacavir/lamivudine or tenofovir/emtricitabine with efavirenz or atazanavir/ritonavir. AIDS 2012; 26: 1371-1385
86. Funderburg N, Kalinowska M, Eason J, et al. Effects of maraviroc and efavirenz on markers of immune activation and inflammation and associations with CD4 cell rises in HIV-infected patients. PLoS One 2010; 5: E13188
87. Satchell CS, O'Halloran JA, Cotter AG, et al. Increased platelet reactivity in HIV-1-infected patients receiving abacavir-containing antiretroviral therapy. J Infect Dis 2011; 204: 1202-1210
88. Baum PD, Sullam PM, Stoddart CA, McCune JM. Abacavir increases platelet reactivity via competitive inhibition of soluble guanylyl cyclase. AIDS 2011; 25: 2243-2248
89. Strategies for Management of Anti-Retroviral Therapy (SMART)/ International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) Study Group and The Data Collection on Adverse events of Anti-HIV Drugs (DAD) Study Group. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS 2008; 22: F17-24
90. Cruciani M, Zanichelli V, Serpelloni G, et al. Abacavir use and cardiovascular disease events: A meta-Analysis of published and unpublished data. AIDS 2011; 25: 1993-2004
91. Ribaudo HJ, Benson CA, Zheng Y, et al. No risk of myocardial infarction associated with initial antiretroviral treatment containing abacavir: Short and long-Term results from ACTG A5001/ALLRT. Clin Infect Dis 2011; 52: 929-940
92. Ding X, Andraca-Carrera E, Cooper C, et al. No association of abacavir use with myocardial infarction: Findings of an FDA meta-Analysis. J Acquir Immune Defic Syndr 2012; 61: 441-447
93. Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIVinfected adults. N Engl J Med 2005; 352: 48-62
94. Gillard BK, Raya JL, Ruiz-Esponda R, et al. Impaired lipoprotein processing in HIV patients on antiretroviral therapy: Aberrant high-density lipoprotein lipids, stability, and function. Arterioscler Thromb Vasc Biol 2013; 33: 1714-1721
95. Enkhmaa B, Anuurad E, Zhang W, et al. HIV disease activity as a modulator of lipoprotein(a) and allele-specific apolipoprotein(a) levels. Arterioscler Thromb Vasc Biol 2013; 33: 387-392
96. Worm SW, Kamara DA, Reiss P, et al. Evaluation of HIV protease inhibitor use and the risk of sudden death or nonhemorrhagic stroke. J Infect Dis 2012; 205: 535-539
97. United States Food and Drug Administration. http: //www.fda.gov/Safety/ MedWatch/SafetyInformation/Safety-RelatedDrugLabelingChanges/ucm 154448.htm. [Accessed 21 May 2013
98. United States Food and Drug Administration. http: //www.fda.gov/Drugs/ DrugSafety/ucm230096.htm. [Accessed 21 May 2013
99. Zhang X, Jordan P, Cristea L, et al. Thorough QT/QTc study of ritonavirboosted saquinavir following multiple-dose administration of therapeutic and supratherapeutic doses in healthy participants. J Clin Pharmacol 2012; 52: 520-529
100. Soliman EZ, Lundgren JD, Roediger MP, et al. Boosted protease inhibitors and the electrocardiographic measures of QT and PR durations. AIDS 2011; 25: 367-377
101. Moreno T, Perez IA, Isasti G, et al. Prevalence and factors associated with a prolonged QTc interval in a cohort of asymptomatic HIV-infected patients. AIDS Res Hum Retroviruses 2013; 29: 1195-1198
102. Soliman EZ, Prineas RJ, Case LD, et al. Ethnic distribution of ECG predictors of atrial fibrillation and its impact on understanding the ethnic distribution of ischemic stroke in the Atherosclerosis Risk in Communities (ARIC) study. Stroke 2009; 40: 1204-1211
103. Cheng S, Keyes MJ, LarsonMG, et al. Long-Term outcomes in individuals with prolonged PR interval or first-degree atrioventricular block. JAMA 2009; 301: 2571-2577
104. Kelly K, Queen S, Adams R, Mankowski J. Maraviroc Prevents SIV-induced Cardiac Dysfunction. 19th Conference on Retroviruses and Opportunistic Infections; Seattle, WA, USA; 2012. Abstract #816
105. Saumoy M, Sanchez-Quesada JL, Martinez E, et al. LDL subclasses and lipoprotein-phospholipase A2 activity in suppressed HIV-infected patients switching to raltegravir: Spiral substudy. Atherosclerosis 2012; 225: 200-207
106. Martinez E, D'Albuquerque PM, Llibre JM, et al. Changes in cardiovascular biomarkers in HIV-infected patients switching from ritonavir-boosted protease inhibitors to raltegravir. AIDS 2012; 26: 2315-2326
107. Masia M, Martinez E, Padilla S, et al. Endothelial function in HIV-infected patients switching from a boosted protease inhibitor-based regimen to raltegravir: A substudy of the SPIRAL study. J Antimicrob Chemother 2013; 68: 409-413
108. Hatano H, Scherzer R, Wu Y, et al. A randomized controlled trial assessing the effects of raltegravir intensification on endothelial function in treated HIV infection. J Acquir Immune Defic Syndr 2012; 61: 317-325
109. Mugavero MJ, Napravnik S, Cole SR, et al. Viremia copy-years predicts mortality among treatment-naive HIV-infected patients initiating antiretroviral therapy. Clin Infect Dis 2011; 53: 927-935